Literature DB >> 26610680

[Functional MR imaging of the liver].

A Wibmer1, R Nolz2, M Trauner3, A Ba-Ssalamah2.   

Abstract

The diagnostics of diffuse liver disease traditionally rely on liver biopsies and histopathological analysis of tissue specimens. However, a liver biopsy is invasive and carries some non-negligible risks, especially for patients with decreased liver function and those requiring repeated follow-up examinations. Over the last decades, magnetic resonance imaging (MRI) has developed into a valuable tool for the non-invasive characterization of focal liver lesions and diseases of the bile ducts. Recently, several MRI methods have been developed and clinically evaluated that also allow the diagnostics and staging of diffuse liver diseases, e.g. non-alcoholic fatty liver disease, hepatitis, hepatic fibrosis, liver cirrhosis, hemochromatosis and hemosiderosis. The sequelae of diffuse liver diseases, such as a decreased liver functional reserve or portal hypertension, can also be detected and quantified by modern MRI methods. This article provides the reader with the basic principles of functional MRI of the liver and discusses the importance in a clinical context.

Entities:  

Keywords:  Diffuse liver disease; Functional imaging; Magnetic resonance imaging; Non-invasive diagnostics; Quantitative imaging

Mesh:

Year:  2015        PMID: 26610680     DOI: 10.1007/s00117-015-0032-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  96 in total

1.  Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis.

Authors:  Henrik Nilsson; Lennart Blomqvist; Lena Douglas; Anders Nordell; Hans Jacobsson; Karin Hagen; Annika Bergquist; Eduard Jonas
Journal:  J Magn Reson Imaging       Date:  2013-10-10       Impact factor: 4.813

2.  [Techniques for quantification of liver fat in risk stratification of diabetics].

Authors:  J-P Kühn; M C Spoerl; C Mahlke; K Hegenscheid
Journal:  Radiologe       Date:  2015-04       Impact factor: 0.635

3.  Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.

Authors:  Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers
Journal:  Liver Transpl       Date:  2012-10       Impact factor: 5.799

4.  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Shwu-Yuan Wei; Jia-Horng Kao; Hsuan-Shu Lee; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2011-08-31       Impact factor: 5.315

5.  In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension.

Authors:  Alejandro Roldán-Alzate; Alex Frydrychowicz; Eric Niespodzany; Ben R Landgraf; Kevin M Johnson; Oliver Wieben; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-11-12       Impact factor: 4.813

6.  Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Minoru Onozuka; Noriyuki Moriyama; Kyongtae T Bae
Journal:  Radiology       Date:  2011-01-19       Impact factor: 11.105

7.  Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study.

Authors:  Lucas McCormack; Henrik Petrowsky; Wolfram Jochum; Katarzyna Furrer; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

8.  Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging.

Authors:  Andreas Wibmer; Alexander M Prusa; Richard Nolz; Thomas Gruenberger; Martin Schindl; Ahmed Ba-Ssalamah
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

9.  Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots.

Authors:  K-L Milner; A B Jenkins; M Trenell; J Tid-Ang; D Samocha-Bonet; M Weltman; A Xu; J George; D J Chisholm
Journal:  J Viral Hepat       Date:  2013-08-12       Impact factor: 3.728

10.  Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis.

Authors:  Aldo J Montano-Loza; Andres Duarte-Rojo; Judith Meza-Junco; Vickie E Baracos; Michael B Sawyer; Jack X Q Pang; Crystal Beaumont; Nina Esfandiari; Robert P Myers
Journal:  Clin Transl Gastroenterol       Date:  2015-07-16       Impact factor: 4.488

View more
  4 in total

1.  Development of a novel rat model of heterogeneous hepatic injury by injection with colchicine via the splenic vein.

Authors:  Yan-Yan Zhang; Chao-Xu Zhang; Yu Li; Xuan Jiang; Yong-Fang Wang; Yang Sun; Jun Wang; Wan-Ying Ji; Yi Liu
Journal:  World J Gastroenterol       Date:  2018-11-28       Impact factor: 5.742

2.  The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

Authors:  Sarah Poetter-Lang; Katharina Staufer; Pascal Baltzer; Dietmar Tamandl; Dina Muin; Nina Bastati; Emina Halilbasic; Jacqueline C Hodge; Michael Trauner; Lili Kazemi-Shirazi; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2018-07-27       Impact factor: 5.315

Review 3.  Quantification of liver function using gadoxetic acid-enhanced MRI.

Authors:  Sarah Poetter-Lang; Nina Bastati; Alina Messner; Antonia Kristic; Alexander Herold; Jacqueline C Hodge; Ahmed Ba-Ssalamah
Journal:  Abdom Radiol (NY)       Date:  2020-10-09

4.  New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients.

Authors:  Feifei Gao; Yi Wei; Tong Zhang; Hanyu Jiang; Qian Li; Yuan Yuan; Shan Yao; Zheng Ye; Shang Wan; Xiaocheng Wei; Lisha Nie; Hehan Tang; Bin Song
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.